Surgical company CMR raises over $200 million for rapid expansion
In a significant development for the surgical robotics industry, CMR Surgical, a global leader in the field, has raised over $200 million in a financing round. The funds will be used to accelerate the commercial expansion of the Versius Surgical Robotic System to more hospitals worldwide, with a major focus on launching Versius in the United States.
The financing round was supported by all the company's existing major investors and includes a new debt investment from Trinity Capital. The funds will enable CMR Surgical to build on the success of Versius, which has already been used in more than 30,000 surgical cases globally across a wide range of specialities.
Versius is the second most utilised soft tissue surgical robot in the world, and its modular design offers increased flexibility, faster setup, and a smaller footprint compared to fixed-tower competitors. This modularity supports hospital OR adaptability and positions Versius well for global expansion, especially in cost-sensitive markets beyond the U.S. and Western Europe, including Asia, Latin America, Eastern Europe, and Africa.
Dan Moore, Non-Executive Chairman at CMR Surgical, expressed confidence in the future of surgical robotics and in CMR as a leader within this space. Massimiliano Colella, CEO of CMR Surgical, expressed gratitude for the financing and stated the company's strategic vision of making robotic-assisted surgery accessible to all patients.
Rob Lake, Senior Managing Director at Trinity Capital, expressed excitement about partnering with CMR and believes Versius will continue to drive a new era in minimally invasive surgery. UK Science Minister and Oxford Cambridge Corridor Champion Lord Vallance also expressed a positive view of the funding round, stating it is a clear vote of confidence in the company, the potential of surgical robotics, and in the UK's life science ecosystem.
Key growth drivers for CMR Surgical and the Versius system include widening adoption in non-U.S. markets due to Versius’ lower cost and scalable platform approach, integration of advanced technologies such as AI-powered navigation, computer vision for tissue classification, and real-time data from visual and force sensors to enhance surgical precision and outcomes, and increasing demand for minimally invasive surgeries that reduce recovery time, pain, and complications.
As part of its growth strategy, CMR is actively expanding its clinical footprint with two ongoing clinical trials: a pioneering paediatrics study and a transoral robotic surgery trial. The company has also recently appointed Chris O’Hara as Commercial President and GM for U.S. operations to lead this growth phase and capitalize on the accelerating demand for its Versius Surgical Robotic System, which has FDA authorization.
With this significant funding round, CMR Surgical is poised to build on Versius’ clinical success and modular technology to drive global market penetration and innovation in robotic-assisted surgery. This aligns with broader industry trends favouring flexible, AI-enhanced robotic platforms offering cost-effective solutions for complex surgical procedures.
- CMR Surgical, a global leader in surgical robotics, has secured over $200 million in financing to accelerate the commercial expansion of its Versius Surgical Robotic System globally, with a major focus on the United States.
- The financing round was supported by all the company's existing major investors, including new debt investment from Trinity Capital, and will enable CMR Surgical to build on the success of Versius, which has already been used in more than 30,000 surgical cases across various specialties.
- With this funding, CMR Surgicals aims to capitalize on the growing demand for minimally invasive surgeries, driven by advanced technologies such as AI-powered navigation, computer vision, and real-time data, reducing recovery time, pain, and complications.
- As part of its growth strategy, CMR is actively expanding its clinical footprint with two ongoing clinical trials, a paediatrics study, and a transoral robotic surgery trial, and has recently appointed Chris O’Hara as Commercial President and GM for U.S. operations to lead this growth phase.
